Introduction
============

Superparamagnetic iron oxide nanoparticle (SPIO)-based molecular imaging agents targeting macrophages have been developed and successfully applied in animal models of myocardial infarction.

Purpose
=======

The purpose of this clinical trial was to investigate whether molecular magnetic resonance imaging (MRI) of macrophages using ferucarbotran (Resovist®) allows improved visualization of the myocardial (peri-)infarct zone compared to conventional gadolinium-based necrosis/fibrosis imaging in patients with acute myocardial infarction.

Methods
=======

The clinical study NIMINI-1 was performed as a prospective, non-randomised, non-blinded, single agent phase III clinical trial. Twenty patients who had experienced either an acute ST-elevation or non-ST-elevation myocardial infarction (STEMI/NSTEMI) were included to this study. Following coronary angiography, a first baseline cardiovascular magnetic resonance (CMR) study (pre-SPIO) was performed within seven days after onset of cardiac symptoms. A second CMR study (post-SPIO) was performed either 10min, 4h, 24h or 48h after ferucarbotran administration. The CMR studies comprised cine-CMR, T2-weighted "edema" imaging, T2\*-weighted cardiac imaging and T1-weighted late-gadolinium-enhancement (LGE) imaging.

Results
=======

The median extent of short-axis in-plane LGE was 28% (IQR 19-31%). Following Resovist® administration the median extent of short-axis in-plane T2\*-weighted hypoenhancement (suggestive of intramyocardial hemorrhage and/or SPIO accumulation) was 0% (IQR 0-9%; p=0.68 compared to pre-SPIO). A significant in-slice increase (\>3%) in the extent of T2\*-weighted "hypoenhancement" (post-SPIO compared to pre-SPIO) was seen in 6/16 patients (38%). However, no patient demonstrated "hypoenhancement" in T2\*-weighted images following Resovist® administration that exceeded the area of LGE.

Conclusions
===========

T2/T2\*-weighted MRI aiming at non-invasive myocardial macrophage imaging using the approved dose of ferucarbotran does not allow improved visualization of the myocardial (peri-) infarct zone compared to conventional gadolinium-based necrosis/fibrosis imaging.
